Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Spero Therapeutics

10/08/2022 22:03

* Spero Therapeutics Inc  SPRO.OQ  reported a quarterly
adjusted
loss of 87 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 93 cents per share.
    * Revenue fell 61.3% to $1.99 million from a year ago;
analysts
expected $1.15 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 87 cents​.
    * The mean earnings estimate of analysts had fallen by
about 39.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Spero Therapeutics Inc shares had risen by 4.8% this
quarter and
lost 95.2% so far this year.
    * The company reported a quarterly loss of $28.68 million.
    * Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 10
at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.93          -0.87          Beat
 Mar. 31 2022      -0.87          -1.01          Missed
 Dec. 31 2021      -0.75          -0.90          Missed
 Sep. 30 2021      -0.66          -0.70          Missed